Syros Pharmaceuticals (SYRS) News Today $0.0016 +0.00 (+45.45%) As of 03:26 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYRS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Rege Nephro buys Tamibarotene-related assets from Syros PharmaceuticalsApril 15, 2025 | msn.comSyros Pharmaceuticals trading resumesMarch 1, 2025 | markets.businessinsider.comSyros Pharmaceuticals Plans to Wind Down OperationsMarch 1, 2025 | marketwatch.comSyros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stockMarch 1, 2025 | markets.businessinsider.comSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationFebruary 28, 2025 | businesswire.comSyros Pharmaceuticals stock hits 52-week low at $0.18 amid steep declineJanuary 29, 2025 | msn.comNancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) StockDecember 5, 2024 | insidertrades.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $36,372.51 in StockNovember 28, 2024 | insidertrades.comSyros Pharmaceuticals Faces Financial Struggles Amid Key ChallengesNovember 18, 2024 | markets.businessinsider.comSyros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRSNovember 15, 2024 | markets.businessinsider.comSyros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setbackNovember 15, 2024 | investing.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock, Short Interest ReportNovember 14, 2024 | benzinga.comJMP Securities downgrades Syros Pharmaceuticals (SYRS) to a HoldNovember 14, 2024 | markets.businessinsider.comSyros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan DefaultNovember 14, 2024 | benzinga.comSyros Pharmaceuticals downgraded to Neutral from Buy at H.C. WainwrightNovember 14, 2024 | finance.yahoo.comTD Cowen Downgrades Syros Pharmaceuticals (SYRS)November 14, 2024 | msn.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of "Buy" by BrokeragesNovember 13, 2024 | marketbeat.comTD Cowen Reiterates "Hold" Rating for Syros Pharmaceuticals (NASDAQ:SYRS)November 13, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Earns "Neutral" Rating from HC WainwrightNovember 13, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Earns "Market Perform" Rating from JMP SecuritiesNovember 13, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Receives Hold Rating from Brookline Capital ManagementNovember 13, 2024 | marketbeat.comSyros Pharmaceuticals trading halted, news pendingNovember 13, 2024 | markets.businessinsider.comSyros Pharmaceuticals (SYRS) was downgraded to a Hold Rating at TD CowenNovember 13, 2024 | markets.businessinsider.comSyros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene OverexpressionNovember 12, 2024 | businesswire.comSyros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.comNovember 4, 2024 | marketbeat.comSyros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)November 4, 2024 | finance.yahoo.comSyros Pharmaceuticals: Promising Breakthrough with Tamibarotene in High-Risk MDSNovember 1, 2024 | markets.businessinsider.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comSyros Pharmaceuticals (NASDAQ:SYRS) Announces Earnings ResultsNovember 1, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Earns Buy Rating from HC WainwrightNovember 1, 2024 | marketbeat.comSyros Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 1, 2024 | finance.yahoo.comSyros Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comSyros Pharmaceuticals, Inc.November 1, 2024 | cnn.comSyros Pharmaceuticals: Promising Prospects with Strong Cash Position and Advancing Phase 3 Trial in HR-MDSNovember 1, 2024 | markets.businessinsider.comSyros Pharmaceuticals (SYRS) Set to Announce Earnings on ThursdayOctober 25, 2024 | marketbeat.comSyros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law FirmOctober 23, 2024 | stockhouse.comSyros Pharmaceuticals (NASDAQ:SYRS) Rating Increased to Hold at StockNews.comOctober 15, 2024 | marketbeat.comSyros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...October 9, 2024 | finance.yahoo.comSyros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.comOctober 7, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock Price Crosses Below Fifty Day Moving Average of $2.91October 2, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 25, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 17, 2024 | prnewswire.comInsider Spends US$161k Buying More Shares In Syros PharmaceuticalsSeptember 15, 2024 | sg.finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) CFO Buys $54,812.65 in StockSeptember 13, 2024 | insidertrades.comInsider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)September 12, 2024 | finance.yahoo.comInsider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)September 12, 2024 | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 9, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRSSeptember 3, 2024 | prnewswire.comSyros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for AllegedSeptember 3, 2024 | prnewswire.comIndividuals With Losses In Syros Pharmaceuticals Inc. Should Join The Schall Law Firm In An Inquiry Into Possible Securities Law ViolationsAugust 30, 2024 | stockhouse.com Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRS Media Mentions By Week SYRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRS News Sentiment▼0.001.03▲Average Medical News Sentiment SYRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRS Articles This Week▼01▲SYRS Articles Average Week Get the Latest News and Ratings for SYRS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Syros Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NCNA News SMFL News VRPX News AIMDW News BCTXW News GDTC News ENGNW News FBIOP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access